Cholangiocarcinoma. - One third of patients with FGFR2 rearrangements showed response to targeted anti-FGFR therapy (pemigatinib) in the second line (post-chemo) setting.

Web

Oct. 4, 2019

SCIENTIFIC

Cholangiocarcinoma.


- One third of patients with FGFR2 rearrangements showed response to targeted anti-FGFR therapy (pemigatinib) in the second line (post-chemo) setting. Responses were not seen in patients with other FGF/FGFR alterations.
ESMO LBA40

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Proffered-Paper-1-Gastrointestinal-tumours-non-colorectal-Invited-Discussant-671O-and-LBA40